Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Q4 2025 Earnings Call January 22, 2026 5:00 PM ESTCompany ParticipantsJohn Pitzer - Corporate Vice President of Corporate ...

Tuesday, January 20, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research ...

The Mila artificial intelligence institute in Quebec is raising a US$100-million venture capital fund with plans to invest in ...

A new study by researchers in Japan offers new insights into how protocells may have inherited and enriched genetic material before modern biology emerged. By exposing mixed phospholipid vesicles to ...

Modern cells are complex chemical entities with cytoskeletons, finely regulated internal and external molecules, and genetic material that determines ...

It's not necessarily the software at fault, though ...

Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance on long-context tasks. RLMs use a programming environment to recursively ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

New Rust release brings major improvements to musl’s DNS resolver and tweaks the standard library to aid global allocators.

Looking for a research and development job? Check out the BioSpace list of 12 companies hiring life sciences professionals like you.

Cancer drugs are always popular biotech investments, but autoimmune disease also figures prominently in the startup ...